BSV portfolio can touch Rs 5K cr in 3-4 yrs: Mankind Pharma's Rajeev Juneja

'We don't want to get into exports with generic or me-too products. We always wanted products with a high level of entry barriers and complexity'

In one of the biggest pharmaceutical (pharma) deals in recent years, Delhi-based Mankind Pharma acquired Mumbai-headquartered specialty pharma company Bharat Serums and Vaccines (BSV) for Rs 13,630 crore on Friday. RAJEEV JUNEJA, managing director (MD) and vice-chairman of Mankind Pharma, spoke to Sohini Das over the phone about the potential of the BSV portfolio to reach a Rs 5,000 crore turnover in three to four years with Mankind’s marketing prowess. Edited excerpts:

Will this deal lead to Mankind Pharma focusing on exports too?

We have been very clear from the beginning that we don’t want to